Prolonged xenokidney graft survival in sensitized NHP recipients by expression of multiple human transgenes in a triple knockout pig
Authors:
- 12 June 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (751) , eadk6152
Abstract
Genetic modification of porcine donors, combined with optimized immunosuppression, has been shown to improve outcomes of experimental xenotransplant. However, little is known about outcomes in sensitized recipients, a population that could potentially benefit the most from the clinical implementation of xenotransplantation. Here, five highly allosensitized rhesus macaques received a porcine kidney from GGTA1 (α1,3-galactosyltransferase) knockout pigs expressing the human CD55 transgene (1KO.1TG) and were maintained on an anti-CD154 monoclonal antibody (mAb)–based immunosuppressive regimen. These recipients developed de novo xenoreactive antibodies and experienced xenograft rejection with evidence of thrombotic microangiopathy and antibody-mediated rejection (AMR). In comparison, three highly allosensitized rhesus macaques receiving a kidney from GGTA1 , CMAH (cytidine monophospho- N -acetylneuraminic acid hydroxylase), and b4GNT2 / b4GALNT2 (β-1,4- N -acetyl-galactosaminyltransferase 2) knockout pigs expressing seven human transgenes including human CD46 , CD55 , CD47 , THBD (thrombomodulin), PROCR (protein C receptor), TNFAIP3 (tumor necrosis factor–α–induced protein 3), and HMOX1 (heme oxygenase 1) (3KO.7TG) experienced significantly prolonged graft survival and reduced AMR, associated with dampened post-transplant humoral responses, early monocyte and neutrophil activation, and T cell repopulation. After withdrawal of all immunosuppression, recipients who received kidneys from 3KO.7TG pigs rejected the xenografts via AMR. These data suggest that allosensitized recipients may be suitable candidates for xenografts from genetically modified porcine donors and could benefit from an optimized immunosuppression regimen designed to target the post-transplant humoral response, thereby avoiding AMR.Keywords
This publication has 61 references indexed in Scilit:
- Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping studyThe Lancet, 2023
- Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate modelKidney International, 2021
- Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantationKidney International, 2019
- CMV drives the expansion of highly functional memory T cells expressing NK‐cell receptors in renal transplant recipientsEuropean Journal of Immunology, 2017
- The promise of organ and tissue preservation to transform medicineNature Biotechnology, 2017
- Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allograftsKidney International, 2016
- Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograftNature Communications, 2016
- Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantationThe Journal of Thoracic and Cardiovascular Surgery, 2014
- Report of the xenotransplantation advisory committee of the international society for heart and lung transplantation:The Journal of Heart and Lung Transplantation, 2000
- Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primatesNature Medicine, 1999